Margaret Foti, PhD, MD (hc), Chief Executive Officer of the American Association for Cancer Research (AACR), was honored with the 2013 Stanley P. Reimann Honor Award for her deep and far-reaching contributions to cancer science and medicine at a celebration hosted by Fox Chase Cancer Center, held recently in Philadelphia.
“I am deeply honored and humbled to receive the 2013 Stanley P. Reimann Honor Award,” said Dr. Foti. “Dr. Riemann was a true pioneer in the cancer research community. His vision and commitment to discovery and collaborative science continue to define the cutting-edge research program conducted at the Fox Chase Cancer Center.
The Stanley P. Reimann Honor Award is bestowed by Fox Chase Cancer Center to individuals from different spheres of influence who bring exceptional ingenuity and expertise to the cancer cause. Previous awardees include Nancy Brinker, C. Everett Koop, Frank Rauscher Jr, and Baruch S. Blumberg. The award was established to perpetuate the memory of Stanley P. Reimann, MD, the founder of the Institute for Cancer Research, which merged with the American Oncologic Hospital to form Fox Chase Cancer Center in 1974.
AACR Career Highlights
Dr. Foti became CEO of the AACR in 1982. Working collaboratively with the elected officers of the AACR, she has provided the continuity of leadership that has been critical to the association’s progress and its mission to prevent and cure cancer. During her tenure, the AACR’s membership has grown from about 3,000 to 34,000 laboratory, translational, and clinical researchers; health-care professionals; students; cancer survivors; and research and patient advocates in the United States and more than 90 other countries.
Dr. Foti’s efforts to accelerate the dissemination of new research findings among scientists and others dedicated to the conquest of cancer have included the launch of seven peer-reviewed scientific journals: Cancer Discovery; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; Cancer Prevention Research; and Cancer Immunology Research. ■
